FDA warns of nationwide recall of lactated Ringer’s injection
B. Braun has recalled two lots of Lactated Ringer’s Injection, 1L, after FDA-posted company testing found particulate matter in the solution. The recall applies to hospitals and healthcare facilities, so patients, caregivers, pharmacists, and clinicians should check lot numbers and follow recall instructions rather than making treatment changes on their own.
B. Braun Medical has recalled two lots of Lactated Ringer’s Injection, 1L, after the FDA posted the company’s notice saying the product may contain particulate matter in solution. The recall was issued nationwide to distributors, hospitals, and healthcare facilities.
For most readers, the key step is simple: if you care for a patient who recently received this IV fluid, or you stock it in a clinic, pharmacy, infusion center, or hospital unit, check the lot numbers and follow the recall instructions. Do not change needed treatment without guidance from a clinician or the facility’s pharmacy team.
What was recalled
According to FDA’s recall notice, the product is B. Braun Lactated Ringer’s Injection, E7500, 1L, identified by product code E7500 and NDC 0264-7750-07. The recalled lots are J4P756 and J4S843. FDA said the product was distributed nationwide to distributors, hospitals, and healthcare facilities.
Why particulate matter matters
FDA says the concern is that loose particles in an IV solution could be infused into the circulatory system if the container is used on a patient. In that situation, the company says there is a reasonable probability of harm that could include pulmonary emboli, blockage of other blood vessels, phlebitis, immune activation, organ dysfunction, hemolysis, and, in severe cases, permanent impairment or death.
That does not mean every exposed patient will be harmed. It does mean IV products are held to a high safety standard because contaminants can enter the bloodstream directly, where they may cause serious problems.
Who should pay attention
This recall is most relevant for hospitals, emergency departments, surgical centers, infusion centers, pharmacists, purchasing teams, and any caregiver managing an inpatient or outpatient infusion. Patients who recently received Lactated Ringer’s Injection from a facility generally should not assume they were affected, but they should ask whether the product from the recalled lots was used in their care.
People most likely to need a quick check are those who had IV fluids, a procedure, or a hospital stay around the time the lots were in distribution. Clinicians and pharmacists should review inventory, quarantine affected stock, and follow the company’s return process.
What to do now
FDA says people and facilities with recalled product should stop using it and arrange for return of the product through the company’s recall process. If you are a patient, the safest next step is to contact the care team or pharmacy that provided the product and ask whether the lot number matches the recall notice.
If you are taking medicine or receiving treatment that depends on IV fluids, do not stop or delay care on your own. FDA notes that in some recalls, stopping treatment can be more harmful than continuing it, so the decision should be made with a clinician or pharmacist.
When to seek help
B. Braun says it had not received reports of adverse events related to this recall at the time of the notice. Still, anyone who thinks they may have had a problem after receiving the product should contact a physician or healthcare provider. Urgent symptoms after an infusion, such as trouble breathing, chest pain, severe swelling, fainting, or a sudden change in mental status, should be treated as an emergency.
People and facilities can also report quality problems or adverse events through FDA’s MedWatch reporting system.
Why recalls are often lot-specific
FDA explains that recalls are classified by risk, and many drug recalls are limited to specific lots or distribution channels rather than every unit of a product. That is because a problem may affect only certain batches made at a certain time. FDA says consumers should check the lot number on the label and follow the instructions in the recall notice or from the company.
For families and caregivers, the practical takeaway is to keep the package information when possible, ask questions if an IV product was used, and rely on the care team for any treatment changes.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
